Age-stratified thresholds of anti-Müllerian hormone improve prediction of polycystic ovary syndrome over a population-based threshold

Abstract

In this issue, Quinn et al. reports their experience on the diagnostic value of the anti-mullerian hormone (AMH) assay for the recognition of polycystic ovary syndrome (PCOS). This subject remains very much debated and, in particular, there is no consensus on a specific threshold discriminating PCOS from normal women. One of the reasons, but certainly not the only one, is the heterogeneity of the control groups between the various studies reported to date.

This article is protected by copyright. All rights reserved.

http://ift.tt/2yDxmLE